Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antigen peptide chain group for treating tumors and application thereof in medicines

A technology of antigenic peptides and drugs, applied in the field of malignant tumor bioimmune drugs, can solve problems such as difficult side effects and non-specificity

Inactive Publication Date: 2018-05-18
天津亨佳生物科技发展有限公司
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, DCs induced by tumor-associated high-expression proteins are not strictly specific, and tissue cells other than tumors also express the same protein, so its side effects are a problem

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antigen peptide chain group for treating tumors and application thereof in medicines
  • Antigen peptide chain group for treating tumors and application thereof in medicines
  • Antigen peptide chain group for treating tumors and application thereof in medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0095] Patient A, female, 65 years old. Lung squamous cell carcinoma, liver metastases, clinical stage IV, lung tumor treated with iodine 125 seed implantation once, progressed after 5 times of vinorelbine single-drug chemotherapy, liver metastases progressed after chemoembolization and iodine 125 seed implantation , EGFR molecular targeting drug resistance. Multiple lung metastases, liver metastases, pleural metastases, bone metastases, abdominal lymph node metastases. A biopsy of the lung lesion was taken, and 488 tumor occurrence and development-related gene panels and HLA typing chips were tested. The results showed that the patient carried EGFR p.L858R, and the HLA typing was HLA-A: A*1101A*3101; HLA-B : B*3501B*4006; HLA-C: C*0303C*0801; HLA-DQB1: DQB1*0401DQB1*0602; HLA-DRB1: DRB1*0405DRB1*1501.

[0096] Combination therapy (hereinafter referred to as "administration") was performed using the antigen peptide chain group for treating tumors of the present invention, on...

Embodiment 2

[0110] Patient B, male, 71 years old, right lung adenocarcinoma, multiple lymph node metastases, no indication for surgery, received pemetrexed + cisplatin intravenous chemotherapy for 6 weeks, progressed after 1 cycle of pemetrexed chemotherapy, and received iodine 125 seed implantation. Progression after entry. After the detection of 488 tumor development-related gene panels and HLA typing chips, the patient carried EGFR p.L858R, NAV3 F2221L, EPHB1N461S mutations, and the HLA typing was HLA-A: A*020101 A*0207; HLA-B: B *4601 B*5101; HLA-C: C*0102 C*150201; HLA-DQB1: DQB1*030302 DQB1*0601; HLA-DRB1: DRB1*080302DRB1*090102.

[0111] Combination therapy was performed using the antigen peptide chain group for treating tumors of the present invention once a week for a total of 6 weeks. The specific selected peptide chains are as follows:

[0112] a) HVKITDFGR

[0113] b) FGRAKLL

[0114] c) GRAKLLGAEEK

[0115] d)KITDFGRAK

[0116] e) HVKITDFGRAK

[0117] f) RAKLLGAEEK

...

Embodiment 3-60

[0121] In Example 3-60, cancer patients of different types and degrees were treated with combinations of different antigen peptide chain groups, once a week for a total of 12 weeks. The results of HLA*A3101-HVKITDFGR Tetramer staining and the changes in lung tumor size before and after treatment in Example 3-60 are similar to those in Example 1-2, and will not be repeated here due to space limitations. The above results can all show that the antigen peptide chain group of the present invention can induce dendritic cells that produce tumors, and dendritic cells as antigen-presenting cells can present antigen information to T cells, interact with T cells, and cause T cells to produce tumors. It specifically kills tumor cells, plays a role in killing tumor cells, and the effect is obvious.

[0122] During the treatment of Examples 1-60, ELISA was used to detect the specific IFN-γ secretion before the antigen peptide chain was used, 3 weeks, 7 weeks, and 11 weeks after the adminis...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an antigen peptide chain group for individualized biological immunotherapy of tumors and application thereof in medicines. The antigen peptide chain group for treating tumors is prepared from combination of any one or at least two amino acid sequences in SEQ ID NO:1-57. The antigen peptide chain group disclosed by the invention can generate dendritic cells of tumors by induction, and then the dendritic cells serving as antigen-presenting cells can present antigen information to T cells so as to interact with the T cells to enable the T cells to generate specific killingtumor cells, thereby achieving the effect of killing tumor cells.

Description

technical field [0001] The invention belongs to the technical field of malignant tumor bioimmune drugs, and in particular relates to an antigen peptide chain group for individualized biological immunotherapy of tumors and its application in medicine. Background technique [0002] At present, the global incidence of malignant tumors is increasing, the mortality rate is high, and the prognosis is poor. The National Cancer Prevention and Research Office of the National Cancer Center released the largest comprehensive analysis of cancer survival data in China in the International Journal of Cancer. The data shows that the 5-year survival rate of cancer in China is 30.9%, which is far lower than that of developed countries; at the same time, the survival rate of rural patients is only half of urban patients. In developed countries, prostate cancer and breast cancer account for the majority. In China, cancers such as lung cancer, gastric cancer, and liver cancer are more common, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06C07K7/08A61K38/08A61K38/10A61P35/00A61P35/02
CPCC07K7/06A61K38/00C07K7/08
Inventor 刘玉强
Owner 天津亨佳生物科技发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com